Insulin aspart: rapid control for postmeal glucose excursions

References

• Khaw K-T, Wareham N, Bingham S, Luben R, Welch A, Day N. Association of hemoglobin A1C with cardiovascular disease and mortality in adults. The European Prospective Investigation into Cancer in Norfolk. Ann. Intern. Med.141, 413–420 (2004).
   PubMed Web of Science ®Google Scholar
• Selby JV, Zhang D. Risk factors for lower extremity amputation in persons with diabetes. Diabetes Care18(4), 509–516 (1995).
   PubMed Web of Science ®Google Scholar
• Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabetes Med.14, 557–585 (1997).
   Google Scholar
• Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med.29, 977–986 (1993).
   Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphoylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPD33). Lancet352, 837–853 (1998).
   PubMed Web of Science ®Google Scholar
• Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent-diabetes mellitus, a randomized prospective 6-year study. Diabetes Res. Clin. Pract.28(2), 103–117 (1995).
   PubMed Web of Science ®Google Scholar
• Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with Type 1 diabetes. N. Engl. J. Med.353, 2643–2653 (2005).
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Economic costs of diabetes in the US. Diabetes Care26, 917–932 (2003).
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes. Diabetes Care29(Suppl. 1), S1–S85 (2007).
   Web of Science ®Google Scholar
• Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among US adults diagnosed with Type 2 diabetes, a preliminary report. Diabetes Care27, 17–20 (2004).
   PubMed Web of Science ®Google Scholar
• Dungan KM, Buse JB, Largay J et al. 1,5-anhydroglucitol and postprandial hyperglycaemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care29(6), 1214–1218 (2006).
   PubMed Web of Science ®Google Scholar
• Gerich JE. Clinical significance, pathogenesis, and management of postprandial hyperglycemia. Arch. Intern. Med.163, 1306–1316 (2003).
   PubMed Web of Science ®Google Scholar
• Monnier L, Mas E, Ginet C et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA295(14), 1681–1687 (2006).
   PubMed Web of Science ®Google Scholar
• Esposito K, Giugliano D, Nappo F, Marfella R. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in Type 2 diabetes mellitus. Circulation110(2), 214–219 (2004).
   PubMed Web of Science ®Google Scholar
• DECODE Study Group. Glucose tolerance and mortality, comparison of WHO and American Diabetic Association diagnostic criteria. Lancet354, 617–621 (1999).
   PubMed Web of Science ®Google Scholar
• Peyrot M, Rubin RR, Lauritzen T et al. Resistance to insulin therapy among patients and providers. Diabetes Care28(11), 2673–2679 (2005).
   PubMed Web of Science ®Google Scholar
• Korytkowski M. When oral agents fail, practical barriers to starting insulin. Int. J. Obes.26(Suppl. 3), S1–S7 (2002).
   Web of Science ®Google Scholar
• Tierney S. Control and disordered eating in Type 1 diabetes. Eat. Weight Disord.12, e30–34 (2007).
   Google Scholar
• Polonsky WH, Anderson BJ, Lohrer PA, Aponte JE, Jacobsen AM, Cole CF. Insulin omission in women with IIDM. Diabetes Care17, 1178–1185 (1994).
   PubMed Web of Science ®Google Scholar
• Bryden K, Neil A, Mayou RA, Peveler RC, Fairburn CG, Dunger DB. Eating habits, body weight and insulin misuse. Diabetes Care22, 1959–1960 (1999).
   Google Scholar
• Carver C. Insulin treatment and the problem of weight gain in Type 2 diabetes. Diabetes Educ.32, 910–917 (2006).
   PubMed Web of Science ®Google Scholar
• McCrimmon RJ, Frier BM. Hypoglycaemia, the most feared complication of insulin therapy. Diabetes Metab.20, 503–512 (1994).
   Web of Science ®Google Scholar
• Starke A, Heinemann L, Hohlmann A, Berger M. The action profiles of human NPH insulin. Diabet. Med.6, 239–244 (1989).
   PubMed Web of Science ®Google Scholar
• Lauritzen T, Faber OK, Binder C. Variation in 1251-insulin absorption and blood glucose concentration. Diabetologia17, 291–295 (1979).
   PubMed Web of Science ®Google Scholar
• Kølendorf K, Bojsen J, Deckert T. Clinical factors influencing the absorption of 125I NPH insulin in diabetic patients. Horm. Metab. Res.5, 274–278 (1983).
   Google Scholar
• Overmann H, Heinmann L. Injection-meal interval, recommendations of diabetologists and how patients handle it. Diabetes Res. Clin. Pract.43, 137–142 (1999).
   PubMed Web of Science ®Google Scholar
• Brange J, Owens DR, Kang S, Vølund A. Monomeric insulins and their experimental and clinical implications. Diabetes Care13, 923–945 (1990).
   PubMed Web of Science ®Google Scholar
• Barnett AH, Owens DR. Insulin analogues. Lancet349, 47–51 (1997).
   PubMed Web of Science ®Google Scholar
• Brange J. The new era of biotech insulin analogues. Diabetologia40(Suppl. 2), S48–S53 (1997).
   PubMedGoogle Scholar
• Brange J, Ribel U, Hansen JF et al. Monomeric insulins obtained by protein engineering and their medical implications. Nature333, 679–682 (1988).
   PubMed Web of Science ®Google Scholar
• Drejer K. The bioactivity of insulin analogues from in vitro receptor binding to in vivo glucose uptake. Diabetes Metab. Rev.8, 259–286 (1992).
   PubMed Web of Science ®Google Scholar
• Kurtzhals P, Schäffer L, Sørensen A et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes49, 999–1005 (2000).
   PubMed Web of Science ®Google Scholar
• Whittingham JL, Edwards DJ, Antson AA, Clarkson JM, Dodson GG. Interactions of phenol and m-cresol in the insulin hexamer, and their effect on the association properties of B28 pro →Asp insulin analogues. Biochemistry37, 11516–11523 (1998).
   PubMed Web of Science ®Google Scholar
• Home PD, Barriocanal L, Lindholm A. Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers. Eur. J. Clin. Pharmacol.55, 199–203 (1999).
   PubMed Web of Science ®Google Scholar
• Cole R. Bioequivalence of insulin aspart produced by two different production methods. Diabetes Med.16, S46 (1999).
   Google Scholar
• Heinemann L, Kapitza C, Starke A, Heise T. Time-action profile of the insulin analogue B28Asp. Diabet. Med.13, 683–684 (1996).
   PubMed Web of Science ®Google Scholar
• Mudaliar SR, Lindberg FA, Joyce M et al. Insulin Aspart (B28 Asp-insulin), a fast-acting analog of human insulin. Diabetes Care22(9), 1501–1506 (1999).
   PubMed Web of Science ®Google Scholar
• Heinemann L, Weyer C, Rauhaus M, Heinrichs S, Heise T. Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart. Diabetes Care21(11), 1910–1914 (1998).
   PubMed Web of Science ®Google Scholar
• Holmes G, Galitz L, Hu P, Lyness W. Pharmacokinetics of insulin aspart in obesity, renal impairment or hepatic impairment. Br. J. Clin. Pharmacol.60, 469–476 (2005).
   PubMed Web of Science ®Google Scholar
• Perriello G, Avogaro A, Bosi E et al. Superior mealtime glucose control with insulin aspart (NovoLog) compared with human insulin in both normal-weight and overweight people with type 2 diabetes – a randomized, stratified, double-blind, crossover trial. Diabetes51(Suppl. 2), A111 (2002).
   Google Scholar
• Perriello G, Pampanelli S, Porcellati F et al. Insulin aspart improves mealtime glycaemic control in patients with Type 2 diabetes, a randomized stratified, double-blind and cross-over trial. Diabet. Med.22, 606–611 (2005).
   PubMed Web of Science ®Google Scholar
• Mortensen H, Lindholm A, Olsen B, Hylleberg B. Rapid appearance and onset of action of insulin aspart in paediatric subjects with Type 1 diabetes. Eur. J. Paediatr.159, 483–488 (2000).
   PubMed Web of Science ®Google Scholar
• Heinemann L, Heise T, Jorgensen LN, Starke AA. Action profile of the rapid acting insulin analogue, human insulin B28Asp. Diabet. Med.10, 535–539 (1993).
   PubMed Web of Science ®Google Scholar
• Rosenfalck A, Thorsby P, Kjems L et al. Improved postprandial glycaemic controls with insulin aspart in Type 2 diabetic patients treated with insulin. Acta Diabetol.37, 41–46 (2000).
   PubMed Web of Science ®Google Scholar
• Kang S, Brange J, Burch A et al. Absorption kinetics and action profiles of subcutaneously administered insulin analogues (AspB9GluB27, AspB10, AspB28) in healthy subjects. Diabetes Care14, 1057–1065 (1991).
   PubMed Web of Science ®Google Scholar
• Lindholm A, McEwen J, Riis AP. Improved postprandial glycaemic control with insulin aspart – a randomized double-blind cross-over trial in Type 1 diabetes mellitus. Diabetes Care22, 801–805 (1999).
   PubMed Web of Science ®Google Scholar
• Nosek L, Heinemann L, Kaiser M et al. No increase in the duration of action with rising doses of insulin aspart. Diabetes53(Suppl. 1), A128 (2003).
   Google Scholar
• Von Mach MA. Brinkmann C, Hansen T et al. Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. Exp. Clin. Endocrinol. Diabetes110, 416–419 (2002).
   PubMed Web of Science ®Google Scholar
• Hedman CA, Lindstrom T, Arnqvist JH. Direct comparison of insulin lispro and aspart shows small differences in plasma insulin profiles after subcutaneous injection in Type 1 diabetes. Diabetes Care24, 1120–1121 (2001).
   PubMed Web of Science ®Google Scholar
• Homko C, Deluzio A, Jimenez C, Kolczynski JW, Boden G. Comparison of insulin aspart and lispro: pharmacokinetic and metabolic effects. Diabetes Care26, 2027–2031 (2003).
   PubMed Web of Science ®Google Scholar
• Cryer PE. Hypoglycemia is the limiting factor in the management of diabetes. Diabetes Metab. Res. Rev.15, 42–46 (1999).
   PubMed Web of Science ®Google Scholar
• Heller SR, Colagiuri S, Vaaler S et al. Hypoglycaemia with insulin aspart, a double-blind randomized, crossover trial in subjects with Type 1 diabetes. Diabet. Med.21, 769–775 (2004).
   PubMed Web of Science ®Google Scholar
• Tamas G, Marre M, Astorga R, Dedov I, Jacobsen J, Lindholm A. Insulin Aspart Study Group. Glycaemic control in Type 1 diabetic patients using optimised insulin aspart or human insulin in a randomised multinational study. Diabetes Res. Clin. Pract.54(2), 105–114 (2001).
   PubMed Web of Science ®Google Scholar
• Home PD, Lindholm A, Riist A for the European Insulin Aspart Study Group. Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus, a randomized controlled trial. Diabet. Med.17, 762–771 (2000).
   PubMed Web of Science ®Google Scholar
• Raskin P, Guthrie RA, Leiter L, Riis A, Jovanovic L. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with Type 1 diabetes. Diabetes Care23(5), 583–588 (2000).
   PubMed Web of Science ®Google Scholar
• Home PD, Lindholm A, Hylleberg B, Round P for the UK Insulin Aspart Study Group. Improved glycemic control with insulin aspart, a multicenter randomized double-blind crossover trial in Type 1 diabetic patients. Diabetes Care21(11), 1904–1909 (2000).
   Web of Science ®Google Scholar
• Home PD, Hallgren P, Usadel KH et al. Pre-meal insulin aspart compared with pre-meal soluble human insulin in Type 1 diabetes. Diabetes Res. Clin. Pract.71(2), 131–139 (2006).
   PubMed Web of Science ®Google Scholar
• DeVries AH, Snoek FJ, Kostense PJ, Masurel N, Heine RJ; on behalf of the Dutch Insulin Pump Study Group. A randomized trial of continuous subcutaneous insulin infusion and intensive injection therapy in Type 1 diabetes for patients with long-standing poor glycemic control. Diabetes Care25, 2074–2080 (2002).
   PubMed Web of Science ®Google Scholar
• Poulsen C. Langkjær L, Worsøe C. Precipitation of insulin products used for continuous subcutaneous insulin infusion. Diabetes Tech. Ther.7(1), 142–150 (2005).
   PubMedGoogle Scholar
• Bode BW, Strange P. Efficacy, safety and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with Type 1 diabetes. Diabetes Care24(1), 69–72 (2001).
   PubMed Web of Science ®Google Scholar
• Bode BW, Sabbah HT, Gross TM, Frederickson LP, Davidson PC. Diabetes management in the new millenium using insulin pump therapy. Diabetes Metab. Res. Rev.18(Suppl. 1), S14–S20 (2002).
   PubMed Web of Science ®Google Scholar
• Chlup R, Zapletová Sečkař P, Chlupová L, Táncosová S, RŘezníčková M. Benefits of insulin aspart vs phosphate-buffered human regular insulin in persons with Type 1 diabetes treated by means of an insulin pump. Biomed. Pap.148(1), 27–32 (2004).
   PubMedGoogle Scholar
• Hirsch IB, Bode BW, Garg S et al. for the Insulin Aspart CSII/MDI Comparison Study Group. Continuous subcutaneous insulin infusion (CSII) of insulin aspart/insulin glargine in Type 1 diabetic patients previously treated with CSII. Diabetes Care28(3), 533–538 (2005).
   PubMed Web of Science ®Google Scholar
• Bolund EA, Grey M, Oesterle A, Fredrickson L, Tamborlane WV. Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycaemia, improve metabolic control, and enhance coping in adolescents with Type 1 diabetes. Diabetes Care22(11), 1779–1784 (1999)
   PubMed Web of Science ®Google Scholar
• Doyle EA, Weinzimer SA, Steffen AT, Ahern JAH, Vincent M, Tamborlane WV. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diabetes Care27(7), 1554–1558 (2004).
   PubMed Web of Science ®Google Scholar
• Bode B, Weinstein R, Bell D et al. Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion. a randomized study in Type 1 diabetes. Diabetes Care25(3), 439–444 (2002).
   PubMed Web of Science ®Google Scholar
• Danne T, Aman J, Schober E et al.; for the ANA 1200 Study group. A comparison of postprandial and preprandial administration of insulin aspart in children and adolescents with Type 1 diabetes. Diabetes Care26(8), 2359–2364 (2003).
   PubMed Web of Science ®Google Scholar
• Poulsen MK, Henriksen JE, Hother-Nielsen O, Beck-Nielsen H. The combined effect of triple therapy with rosiglitazone, metformin and insulin aspart in type 2 diabetic patients. Diabetes Care26, 3273–3279 (2003).
   PubMed Web of Science ®Google Scholar
• de Boer H, Jansen M, Koerts J, Vershoor L. Prevention of weight gain in Type 2 diabetes requiring insulin treatment. Diabetes Obes. Metab.6, 114–119 (2004).
   PubMed Web of Science ®Google Scholar
• Pala L, Mannucci E, Dicembrini I, Rotella CM. A comparison of mealtime insulin aspart and human insulin in combination with meformin in Type 2 diabetes patients. Diabetes Res. Clin. Pract. DOI: 10.1016/j.diabres.2007.02.010 (2007) (Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Bretzel RG, Medding J, Arnolds S, Linn T. A Direct efficacy and safety comparison of insulin aspart, human soluble insulin, and human premix insulin (70/30) in patients with Type 2 diabetes. Diabetes Care27(5), 1023–1027 (2004).
   PubMed Web of Science ®Google Scholar
• Garber AJ, Wahlen J, Wahl T et al. Attainment of glycaemic goals in Type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1–2–3 study). Diabetes Obes. Metab.8(1), 58–66 (2006).
   PubMed Web of Science ®Google Scholar
• Garber AJ, Ligthelm R, Christiansen JC, Liebl A. Premixed insulin treatment for Type 2 diabetes, analogue or human? Diabetes Res. Metab. DOI: 10.1111/j.1463–13262006.00654x (2007) (Epub ahead of print).
   Google Scholar
• Kapitza C, Rave K, Ostrowski K, Heise T, Leinemann L. Reduced postprandial glycaemic excursion with biphasic insulin aspart 30 injected immediately before a meal. Diabet. Med.21, 497–501 (2004).
   Google Scholar
• Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal–bolus therapy for patients with Type 1 diabetes. Diabetologia47(4), 622–629 (2004).
   PubMed Web of Science ®Google Scholar
• Raslova K, Bogoev M, Raz I, Leth G, Gall MA, Hancu N. Insulin detemir and insulin aspart, a promising basal–bolus regimen for Type 2 diabetes. Diabetes Res. Clin. Pract.66(2), 193–201 (2004).
   PubMed Web of Science ®Google Scholar
• Temple R, Aldridge V, Greenwood R, Heyburn P, Sampson M, Stanley K. Association between outcome of pregnancy and glycaemic control in early pregnancy in Type 1 diabetes, population based study. Br. Med. J.325, 1275–1276 (2002).
   PubMed Web of Science ®Google Scholar
• Mathiesen ER, Kinsley B, Amiel SA et al.; on behalf of the Insulin Aspart Pregnancy Study Group. Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy. A randomized trial of insulin aspart versus human insulin in 322 pregnant women. Diabetes Care30(4), 771–776 (2007).
   PubMed Web of Science ®Google Scholar
• Pettitt DJ, Ospina P, Howard C, Zisser H, Jovanovic L. Efficacy, safety and lack of immunogenicity of insulin aspart versus regular human insulin for women with gestational diabetes mellitus. Diabet. Med. (2007) (In Press).
   PubMed Web of Science ®Google Scholar
• Bott U, Ebrahim S, Hirschberger S, Skovlund SE. Effect of the rapid acting insulin analogue insulin aspart on quality of life and treatment satisfaction in patients with Type 1 diabetes. Diabet. Med.20, 626–634 (2003).
   PubMed Web of Science ®Google Scholar
• Ottesen J, Nilsson P, Jami J et al. The potential immunogenicity of human insulin and insulin analogues evaluated in a transgenic mouse model. Diabetologia37, 1178–1185 (1994).
   PubMed Web of Science ®Google Scholar
• Brunner G, Hirschberger S, Sendlhofer G. Postprandial administration of the insulin analogue insulin aspart in patients with Type 1 diabetes mellitus. Diabet. Med.17, 371–375 (2000).
   PubMed Web of Science ®Google Scholar
• Pettitt DJ, Ospina P, Kolaczynski JW, Jovanovic L. Comparison of an insulin analog, insulin aspart, and regular human insulin with no insulin in gestational diabetes mellitus. Diabetes Care26, 183–186 (2003).
   PubMed Web of Science ®Google Scholar
• Robinson RT, Harris ND, Ireland RH, Lindholm A, Heller SR. Comparative effect of human soluble insulin and insulin aspart upon hypoglycaemia-induced alterations in ardiac repolarization. Br. J. Clin. Pharmacol.55, 246–251 (2003).
   PubMed Web of Science ®Google Scholar
• Jonsson B; CODE-s Advisory Board. Revealing the cost of Type 2 diabetes in Europe. Diabetologia45(7), S5–S12 (2002).
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine WJ et al. Validation of the CORE diabetes model against epidemiological and clinical studies. Curr. Med. Res. Opin.20(Suppl. 1), S27–S40 (2004).
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine WJ, Smith I, Witterup-Jensen KU. Cost–effectiveness of detemir-based basal-bolus therapy vs NPH-based basal–bolus therapy for Type 1 diabetes in a UK setting, an economic analysis based on meta-analysis results of four clinical trials. Curr. Med. Res. Opin.20, 1729–1746 (2004).
   PubMed Web of Science ®Google Scholar
• Polonsky KS, Given BD, Hirsch LJ et al. Abnormal patterns of insulin secretion in non-insulin dependent diabetes mellitus. N. Engl. J. Med.318(19), 1231–1239 (1988).
   PubMed Web of Science ®Google Scholar